IP Library Granted Patent US 8,093,062
Granted Patent B2
US 8,093,062 · App. 13/012,831 · Granted Jan 10, 2012

Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,093,062
App. No.
13/012,831
Granted
Jan 10, 2012
Kind
B2
Abstract

The invention is directed to droplet actuator devices and assay methods. The method may include, among other things, a method of conducting enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil, the method including incubating a droplet in oil, the droplet preferably comprising an umbelliferone substrate, a sample, and a cyclodextrin compound. The methods may further include a method of substantially eliminating cross-contamination between droplets in enzymatic containing substrate-based bioassays. The method may include immobilization of the enzymatic substrate including forming an inclusion complex with the substrate for stabilizing the substrate within an aqueous environment, wherein the inclusion complex may be formed using cyclodextrins. In yet another embodiment, the invention may provide a method of enhancing hydrolysis of enzymatic substrates. The methods may further include a method of forming an inclusion complex with the substrate for stabilizing the substrate within an aqueous environment, wherein the substrate may be a 4-MU- or HMU containing substrate. The inclusion complex may be formed using cyclodextrin.

Claims (7)

1. A method of conducting an assay, the method comprising (a) incubating a droplet in oil, the droplet comprising an umbelliferone substrate, a sample potentially comprising an enzyme which cleaves the umbelliferone substrate, and a cyclodextrin compound; and (b) detecting a signal emitted from the droplet.

2. The method of claim 1 wherein the cyclodextrin compound is selected from the group consisting of α-cyclodextrins, β-cyclodextrins, and γ-cyclodextrins, and analogs and derivatives of the foregoing.

3. The method of claim 1 wherein the umbilliferone substrate is selected from the group consisting of alkylumbelliferyl-α-L-iduronides, 4-methylumbelliferyl-α-L-iduronide, 4-methylumbelliferyl-α-L-iduronide-2-sulfate, 4-methylumbelliferyl-α-L-idopyranosiduronic acid, 4-methylumbelliferyl-α-L-fucoside, 4-methylumbelliferyl-α-L-mannoside, 4-methylumbelliferyl-β-D-mannoside, 4-methylumbelliferyl β-D-N-acetylglucosaminide, 4-methylumbelliferyl β-D-N-acetylglucosaminide sulfate, alkylumbelliferyl-β-D-glycosides, methylumbelliferyl-β-D-glycosides, 4-methylumbelliferyl-α-D-galactoside, 4-methylumbelliferyl-β-D-galactoside, 4-methylumbelliferyl-β-D-glucouronic acid, phenolphthalein-β-D-glucuronic acid, ethylumbelliferyl-β-D-glycosides, multifluoroethylumbelliferyl-β-D-glycosides, pentafluoroethylumbelliferyl-β-D-glycosides, pentafluoroethylumbelliferyl-β-D-glucoside, umbelliferylchiotriosides, 4-alkyumbelliferylchiotrioside, 4-methylumbelliferylchiotrioside, 4-methylumbelliferyl-β-galactose, 4-alkyumbeliferrone phosphates, 4-methylumbeliferrone phosphate, 6-alkanoylamido-4-methylumbelliferones, substrates comprising a 4-methyllumbelliferyl group, 6-hexadecanoylamido-4-methylumbelliferone, 4-methyllumbelliferyl-β-D-glucosaminide, 4-methylumbelliferyl-α-neuraminic acid, 4-methylumbelliferyl-α-D-N-acetylgalactosaminide, and their functional analogs and derivatives.

4. The method of claim 1 wherein the incubating is performed within droplets controlled by a droplet actuator.

5. The method of claim 4 wherein the droplets are controlled using electrode mediated droplet operations.

6. The method of claim 4 wherein the droplets are controlled using electrowetting mediated droplet operations.

7. The method of claim 4 wherein the droplets are controlled using dielectrophoresis mediated droplet operations.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 1, 2011
From: ADVANCED LIQUID LOGIC, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026679/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2011
From: SAHA, SANJAY; RAOLJI, GAJENDRASINH BALVANTSINH; DAYAM, RAVEENDRA
To: GVK BIOSCIENCES PRIVATE LIMITED
Reel/Frame 025842/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2011
From: GVK BIOSCIENCES PRIVATE LIMITED
To: ADVANCED LIQUID LOGIC
Reel/Frame 025842/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2011
From: WINGER, THEODORE; ECKHARDT, ALLEN E; GRAHAM, CARRIE; SISTA, RAMAKRISHNA; PAMULA, VAMSEE K; WANG, TONG; XIONG, YALIN; WU, NING
To: ADVANCED LIQUID LOGIC
Reel/Frame 025842/0754 →
Continuity (14)
Continuation In Part 12531844
Continuation In Part 13012831
Continuation PCTUS2010061118 · Dec 10, 2010
Provisional Application 60896341 · Mar 22, 2007
Provisional Application 61288633 · Dec 21, 2009
Provisional Application 61290296 · Dec 28, 2009
Provisional Application 61325580 · Apr 19, 2010
Provisional Application 61334376 · May 13, 2010
Provisional Application 61359943 · Jun 30, 2010
Provisional Application 61378705 · Aug 31, 2010
Provisional Application 61382564 · Sep 14, 2010
Provisional Application 61392633 · Oct 13, 2010
Provisional Application 61406380 · Oct 25, 2010
Related Publication 20110118132A1 · May 19, 2011